CPIC 2026 | Hello, "Lu Lu" – The Mascot Is Officially Named!
"Upholding Integrity, Auspicious Fortune"
Time：
2026-06-06 21:45
Author：
xieyijun
When FDA Starts "Copying" China's Homework
FDA Eases Regulations on CGT Once Again
Time：
2026-06-06 21:34
Author：
xieyijun
Time：
2026-06-06 13:50
Author：
xieyijun
CPIC 2026 | Peptide Drug R&D Frontier Session – Agenda Release
we look forward to exploring the future frontiers of peptide therapeutics with you.
Time：
2026-06-05 10:18
Author：
xieyijun
From Being Dropped to Rocking ASCO: The Road to Revolution's Turnaround
Revolution dropped a bombshell.
Time：
2026-06-04 17:36
Author：
xieyijun
Developing New Drugs in China: A Perspective from a Small U.S. Biotech
How to Balance Risk and Reward?
Time：
2026-06-03 18:04
Author：
xieyijun
Three Acquisitions in One Day: The Strategy Behind Eli Lilly's "Feeding Frenzy"
The Ambition of a Trillion-Dollar Market Cap Giant
Time：
2026-06-02 18:01
Author：
xieyijun
ASCO 2026: China's New Drug Army Closes in on Keytruda
Who Is Rewriting the Future of First-Line Lung Cancer Treatment?
Time：
2026-06-01 18:09
Author：
xieyijun
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务